NCT06714214 PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin
| NCT ID | NCT06714214 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 152 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 152 participants in total. It began in 2024-10-01 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years; * diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria) * need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice * Obtaining informed consent Exclusion Criteria: * CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care; * need for RRT (any type and modality) in the 14 days prior to enrolment; * diagnosis of AKD/CKD/ESRF on admission; * Discontinuation of CRRT under conditions that do not comply with the criteria established by the study; * Need for CRRT not associated with AKI condition (e.g. elimination of toxicants); * pregnant women; * presence of known thyreopathy * Continuous use of corticosteroids * patient with known neoplastic disease.
Contact & Investigator
Francesco Marino, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06714214 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06714214 currently recruiting?
Yes, NCT06714214 is actively recruiting participants. Contact the research team at francesco.marino@aosp.bo.it for enrollment information.
Where is the NCT06714214 trial being conducted?
This trial is being conducted at Bologna, Italy, Bologna, Italy.
Who is sponsoring the NCT06714214 clinical trial?
NCT06714214 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Francesco Marino, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 152 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.